Labcyte Collaborating with AstraZeneca on Acoustic Sample Handling for Mass Spec Analysis | GenomeWeb

NEW YORK (GenomeWeb News) – Labcyte said today that it is collaborating with AstraZeneca on applying its acoustic liquid handling technology to mass spec-based drug discovery work.

The collaboration will focus on using Labcyte's technology for direct loading of samples into mass spectrometers, which, the company said, could enable high-throughput, low-cost, label-free mass spec analyses. AstraZeneca aims via the project to expand such mass spec analyses throughout its entire drug discovery and development process.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: experts say race is not a sufficient proxy for studying human genetic diversity and more.

Technology Review writes that CRISPR/Cas9 gene editing firm Editas' success may hinge on a patent case.

Researchers unearthed a bioinformatics error in the Science paper reporting the first ancient African genome, and the authors are seeking an erratum.

A boy's cystic fibrosis carrier status was revealed by a teacher to the parents of children with CF who then sought the boy's transfer to another school, leading to a lawsuit.